AC Immune SA (ACIU): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACIU Stock Price Chart Interactive Chart >
ACIU Price/Volume Stats
|Current price||$2.76||52-week high||$5.41|
|Prev. close||$2.57||52-week low||$2.06|
|Day high||$2.78||Avg. volume||87,911|
|50-day MA||$2.83||Dividend yield||N/A|
|200-day MA||$3.34||Market Cap||230.60M|
AC Immune SA (ACIU) Company Bio
AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.
Most Popular Stories View All
ACIU Latest News Stream
|Loading, please wait...|
ACIU Latest Social Stream
View Full ACIU Social Stream
Latest ACIU News From Around the Web
Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and immunogenicity of ACI-35 and JACI-35, developed in collaboration with Janssen PharmaceuticalsCollaboration partner Genentech/Roche to present pharmacodynamic effects of semorinemab on plasma and CSF Tau biomarkers from “Lauriet” Phase 2 trial in mild-to-moderate Alzheimer’s diseaseBanner Alzheimer’
LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies London Healthcare Conference, which is taking place from November 15 – 17, 2022. During the fireside chat, AC Immune’s CEO Dr. Andrea Pfeifer will provide an overview of the
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA (ACIU - Research Report) today and set a price target of $16.00. The company's shares closed last Friday at $2.90.According to TipRanks, Fein is an analyst with an average return of -10.4% and a 34.00% success rate. Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, ACADIA Pharmaceuticals, and Amarin.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $16.00 average price target.
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ACIU Price Returns